Ritonavir News and Research

RSS
Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Does interferon therapy work in COVID-19?

Does interferon therapy work in COVID-19?

Scientists discover two anti-inflammatory drugs that inhibit COVID-19 infection

Scientists discover two anti-inflammatory drugs that inhibit COVID-19 infection

Study evaluates the effectiveness of interferon beta 1b in COVID-19 pneumonia

Study evaluates the effectiveness of interferon beta 1b in COVID-19 pneumonia

The use of rheumatoid arthritis drug sarilumab in severe COVID-19 pneumonia

The use of rheumatoid arthritis drug sarilumab in severe COVID-19 pneumonia

Chasing the elusive dream of a COVID cure

Chasing the elusive dream of a COVID cure

Lessons for COVID-19 from 2009 H1N1

Lessons for COVID-19 from 2009 H1N1

Could JAK blockers help treat COVID-19?

Could JAK blockers help treat COVID-19?

Antiviral cocktail may help treat mild COVID-19 patients

Antiviral cocktail may help treat mild COVID-19 patients

Scientists launch clinical trial to test the efficacy of HIV drug against COVID-19 infection

Scientists launch clinical trial to test the efficacy of HIV drug against COVID-19 infection

COVID-19 can trigger serious inflammatory-related cardiovascular problems

COVID-19 can trigger serious inflammatory-related cardiovascular problems

Is the confidence in hydroxychloroquine for the management of COVID-19 justified?

Is the confidence in hydroxychloroquine for the management of COVID-19 justified?

New clinical trial to test two drugs for prophylactic treatment of COVID-19 contact persons

New clinical trial to test two drugs for prophylactic treatment of COVID-19 contact persons

HIV-1 and influenza antivirals not effective for treating mild-to-moderate COVID-19 cases

HIV-1 and influenza antivirals not effective for treating mild-to-moderate COVID-19 cases

Research suggests Nelfinavir and Cepharanthine as potential anti-SARS-CoV-2 agents

Research suggests Nelfinavir and Cepharanthine as potential anti-SARS-CoV-2 agents

China with the world: COVID-19 experts dialogues - the 4th talk transcript

China with the world: COVID-19 experts dialogues - the 4th talk transcript

Cost of ‘repurposing’ existing drugs to treat COVID-19

Cost of ‘repurposing’ existing drugs to treat COVID-19

Remdesivir shows promise in post-infection treatment for COVID-19 disease

Remdesivir shows promise in post-infection treatment for COVID-19 disease

Will 'old faithful' tuberculosis BCG vaccine work against COVID?

Will 'old faithful' tuberculosis BCG vaccine work against COVID?

Critical guidance to identify COVID-19 patients at risk of drug-induced sudden cardiac death

Critical guidance to identify COVID-19 patients at risk of drug-induced sudden cardiac death

Projects to develop COVID-19 vaccines receive U.K. gov’t funding

Projects to develop COVID-19 vaccines receive U.K. gov’t funding